
Nasim Izadi,1 Hossein Samadi Kafil21Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; 2Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Hossein Samadi Kafil, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Email kafilhs@tbzmed.ac.irAbstract: Multidrug-resistant enterococci, particularly vancomycin-resistant enterococci (VRE), represent an important clinical challenge because of their antimicrobial resistance, intestinal persistence, and potential for transmission and infection. The limited effectiveness of conventional antimicrobial approaches in preventing intestinal colonization has increased interest in microbiome-based strategies, including traditional probiotics and next-generation probiotics (NGPs). Traditional probiotics may inhibit enterococci through competitive exclusion, bacteriocin and organic acid production, epithelial barrier support, immune modulation, and microbiome-mediated effects. Importantly, probiotic activity is generally strain-specific and may vary substantially among microorganisms. NGPs, including Akkermansia muciniphila, Faecalibacterium prausnitzii, Clostridium butyricum, and engineered probiotic platforms, offer additional microbiome-based approaches, although direct evidence against enterococci remains limited and varies across experimental models. Overall, current evidence supports the potential of probiotic and NGP-based strategies to influence enterococcal colonization, but most evidence remains preclinical, with limited direct clinical validation. Additional studies are required to establish strain-specific efficacy, safety, mechanisms of action, and clinical applicability before these approaches can be considered established preventive or therapeutic strategies.Keywords: probiotics, postbiotics, Enterococcus faecalis, Enterococcus faecium, infection, resistance, VRE
Samira Ranjbar,1 Afsoon Asadollahi,2 Fatemeh Ghanimati,3 Farzaneh Rafie Sedaghat,4 Hossein Samadi Kafil51Student Research Committee, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 2Department of Maxillofacial Medicine, Faculty of Dentistry, Urmia University of Medical Sciences, Urmia, Iran; 3Research Center for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 4Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 5Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Afsoon Asadollahi; Hossein Samadi Kafil, Email afsoon.asadollahi@gmail.com; Kafilhs@tbzmed.ac.irAbstract: Postbiotics—non-viable microbial components or metabolites derived from probiotics—have emerged as promising modulators of the gut microbiota (GM), offering probiotic-like health benefits without the risks associated with live microorganisms. The GM is a crucial determinant of human health, and its disturbance (known as dysbiosis) is closely linked to conditions such as inflammatory bowel disease (IBD), colorectal cancer (CRC), sepsis, and metabolic syndromes. This review uniquely synthesizes mechanistic insights with therapeutic perspectives and summarizes current knowledge of the therapeutic potential of postbiotics to restore microbial balance and maintain intestinal homeostasis. Bioactive postbiotic molecules, including short-chain fatty acids (SCFAs), bacteriocins, exopolysaccharides, antimicrobial peptides, and vitamins, play key roles in inhibiting pathogens, enhancing beneficial bacterial populations, modulating immune responses, and strengthening epithelial barriers, and could also serve as an alternative to antibiotics. Postbiotics demonstrated therapeutic potential across multiple diseases, including IBD, CRC, metabolic syndrome, sepsis, and antibiotic-resistant infections, primarily through modulation of the GM, enhancement of intestinal barrier integrity, and regulation of immune responses. SCFAs, such as butyrate, reduce inflammation in ulcerative colitis; propionate induces apoptosis in gastric cancer cells. Most of the data in this area are preclinical, and further studies are needed. Evidence from preclinical and mechanistic studies suggests that postbiotics may represent a safe, effective alternative or adjunct to probiotics and antibiotics in managing GM-associated disorders.Keywords: probiotics, postbiotics, metabolites, SCFA, immunomodulation, gut microbiota
Cristina Rosado Alonso,1 Monica Ruiz Pons,1 Marina Gutiérrez Vilar,1 Alejandra Pérez Rodríguez,1 Jose Marrero Castro21Section of Pediatric Nutrition, Nuestra Señora de Candelaria University Hospital, Santa Cruz de Tenerife, Spain; 2Department of Information Technologies, Nuestra Señora de Candelaria University Hospital, Santa Cruz de Tenerife, SpainCorrespondence: Cristina Rosado Alonso, Section of Pediatric Nutrition, Nuestra Señora de Candelaria University Hospital, General del Rosario Road 145, Santa Cruz de Tenerife, 38010, Spain, Tel +34922612151, Email cristi.cristina.ra@gmail.comAbstract: Ketogenic dietary therapy (KDT) is an established treatment for drug-resistant epilepsy and metabolic conditions such as GLUT1-DS. Its efficacy requires strict maintenance of prescribed macronutrient ratios across all care settings. However, KDT continuity is frequently disrupted during hospital admissions and transitions due to organizational constraints, limited menu flexibility, uncertainty regarding food composition, and fragmented communication between hospital and community services. To address these challenges, we conducted a narrative literature review and present a multidisciplinary care approach centered on a dedicated dietitian acting as a care coordinator. The core of this intervention is the Ketogenic Menu Adaptation Sheet (KMAS), an Excel-based decision-support tool developed to translate prescribed caloric requirements and ketogenic ratios into precise, gram-based food exchanges. The dietitian utilizes the KMAS as a vital link between clinical prescriptions and practical food preparation. In the hospital setting, the coordinator uses the tool to rapidly generate ratio-consistent meals from available ingredients, minimizing calculation errors and enabling timely dietary adjustments. Upon discharge, the dietitian leverages the same tool to standardize macronutrient equivalences for families and schools, ensuring seamless continuity of care. The practical application of this coordinated approach is illustrated through two educational case scenarios from routine pediatric practice: (1) inpatient recalibration of the ketogenic ratio following a loss of ketosis, and (2) inpatient initiation of KDT for pharmacoresistant epilepsy. These cases are included as illustrative examples rather than as formal validation of the approach. The coordinated approach, combining a dedicated healthcare professional with the KMAS, may help reduce calculation errors and support cross-setting communication to maintain prescribed ketogenic ratios. Prospective validation studies are needed to confirm these benefits.Keywords: ketogenic dietary therapy, drug-resistant epilepsy, healthcare coordinator, menu adaptation tool
Ara KirakosyanPure Green Pharmaceuticals Inc., West Bloomfield, MI, USACorrespondence: Ara Kirakosyan, Email akirakosyan@pgpharma.co